Company profile
Liquidia Corporation
NASDAQ: LQDA · Healthcare · Medical - Pharmaceuticals
#306 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
59CFH 60DQ 50GM 66SS 69
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ growth stability, return on equity
Methodology →Revenue TTM
$288.1M
Rev growth YoY (TTM)
+1936.7%
Net income (FY)
-$68.9M
Employees
216
as of 2026-08-06
Market cap
$7.9B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$158.3M$158.3M2025
Net income-$68.9M-$68.9M2025
Operating income-$51.4M-$51.4M2025
Total assets$327.9M$327.9M2025
Liabilities$283.2M$283.2M2025
Equity$44.7M$44.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product94%
Service6%
By geography
Not disclosed.
The read
What is Liquidia Corporation’s revenue?
Liquidia Corporation booked $158.3M in FY2025 revenue, growing 1031% year over year — faster than 96% of Healthcare companies we track, at a -43.5% net margin.
Peers · Healthcare
Maze Therapeutics, Inc.49DPacific Biosciences of California, Inc.55CMariMed Inc.66BHeron Therapeutics, Inc.58CAirSculpt Technologies, Inc.58CMacroGenics, Inc.54DNeighbors
Wake →Key facts
CEORoger A. Jeffs
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersMorrisville, NC
ExchangeNASDAQ: LQDA
Employees216
IPO date2018-07-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.